dpp-4 inhibitor and glp-1 receptor agonist combination not recommended guideline Dipeptidyl peptidase-4 (DPP-4) inhibitors: dosing, dose adjustment Insights into the Roles of

Learn what patients and prescribers should know about lean mass, protein, and exercise.

Learn about insurance coverage, prior authorizations, and steps to secure the best plan for your needs

In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need

If you are taking medications or have a medical condition, speak with your provider before use

But theres a tradeoff

With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health